Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250430 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
A Phase 1 study, sponsored by Novan.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02250430: Completed Phase 1 study, sponsored by Novan.
NCT02250430 is a Phase 1 study that has completed, run by Novan. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02250430, a Phase 1 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
In this study, color (erythema) and pH will be measured on 3 consecutive days after application of 2 doses of SB204 to the cheeks of healthy volunteers.
Interventions
- DRUG SB204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT02250430 record still lists
NCT02250430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which SB204 is the first listed.
NCT02250430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02250430 about?
NCT02250430 is a clinical study titled "A Phase 1 Study Assessing Local Cutaneous Effects of SB204". In this study, color (erythema) and pH will be measured on 3 consecutive days after application of 2 doses of SB204 to the cheeks of healthy volunteers.
What is the current status of trial NCT02250430?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02250430?
The interventions under investigation include: SB204 (DRUG).
Who is sponsoring clinical trial NCT02250430?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02250430's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia